Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3361282 | International Journal of Antimicrobial Agents | 2006 | 6 Pages |
Abstract
Many issues need to be addressed by the Intensive Care Unit physician in the decision-making process regarding antifungal therapy for Candida infection, most importantly pharmacokinetic concerns and/or organ failure limitations. In addition, the extensive use of antifungal agents can select for Candida spp. that exhibit decreased susceptibility to these agents. However, the risk appears low, even in the case of prophylactic or pre-emptive antifungal therapy, but this needs to be confirmed in large-scale studies.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Philippe Montravers, Khalil Jabbour,